Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Jenscare Scientific Co., Ltd.
寧波健世科技股份有限公司
(A joint stock Company incorporated in the People's Republic of China with limited liability)
(Stock Code: 9877)

VOLUNTARY ANNOUNCEMENT PRESENTATION OF THE 6-MONTH FOLLOW-UP RESULTS OF TRAVEL III AND THE 2-YEAR FOLLOW-UP RESULTS OF TRAVEL II OF THE LUX-VALVE PLUS CLINICAL STUDY AT TCT 2026 IN THE UNITED STATES

This announcement is made by Jenscare Scientific Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to provide the shareholders and potential investors of the Company with updated information in relation to the latest business and new product development of the Group.

The board ("**Board**") of directors ("**Directors**") of the Company is pleased to announce that recently, the 6-month follow-up results of the multi-center randomized controlled clinical trial ("**TRAVEL III**") and the 2-year long-term follow-up results of the multi-center clinical trial ("**TRAVEL II**") of the LuX-Valve Plus transvenous tricuspid valve replacement system were released at 2026 Transcatheter Cardiovascular Therapeutics Conference (TCT 2026), demonstrating good safety performance, promising durability and sustainable efficacy results of the Company's product which are expected to address a broad range of unmet clinical needs.

6-MONTH FOLLOW-UP RESULTS OF THE LUX-VALVE PLUS TRAVEL III STUDY

TRAVEL III is a prospective, multi-center, randomized controlled clinical trial conducted in China, which primarily evaluates the safety and efficacy of LuX-Valve Plus combined with optimal medical therapy (TTVR+OMT) compared with optimal medical therapy (OMT) solely in application on patients with severe TR.

A total of 118 subjects received treatment in this study, including 76 cases in the TTVR+OMT group and 42 in the OMT group. Patients from the TTVR+OMT group had a median age of 73.0 and median STS score (TVR) of 8.8%, among them, 54.0% (per slide) developed Severe TR, 31.6% Massive TR, and 14.4% (per slide) Torrential TR. Patients from the OMT group had a median age of 73.5 and median STS score (TVR) of 8.3%, among them, 54.8% developed Severe TR, 42.9% Massive TR, and 2.3% Torrential TR. In the study, 42.1% of subjects received valves of 55 mm or larger. The LuX-Valve Plus is available in seven sizes ranging from 40mm to 70mm, covering a wide range of annular sizes.

Patients with severe TR had limited clinical treatment options, indicating a huge unmet clinical need. TRAVEL III provides the first randomized controlled evidence demonstrating that transjugular tricuspid valve replacement using the LuX-Valve Plus offers clinical benefits for patients with severe tricuspid regurgitation who are at high surgical risk.

The clinical results showed:

(1) the procedural success rate was 98.7% (75/76); and

(2) the average device operation time was 37.1±18.4 minutes.

The efficacy results showed:

(1) Under the primary efficacy evaluation criteria, defined as the composite endpoint event rate 6 months after treatment, consisting of patient survival, no rehospitalization due to heart failure, ≥1+ class TR reduction, and ≥1 NYHA cardiac function improvement class, the target achievement rate was 82.9% in the TTVR+OMT group, way outperforming 4.8% in the OMT group, with a rate difference of 78.1% (95% CI 67.5–88.8; P< 0.001).

(2) In terms of improvement in the tricuspid regurgitation grade, all patients from the TTVR+OMT group of the 6-month follow-up showed ≥1 grade TR reduction, with 93.2% developing moderate or lower TR and a mean transvalvular pressure gradient for 6-month post-operation of 2.1±1.1 mmHg, suggesting good valve function;

(3) In terms of New York Heart Association cardiac function improvement, 88.0% of patients from the TTVR+OMT group had their postoperative cardiac function improved by ≥1 class, far better than the OMT group (34.38%);

The safety results showed:

Composite Events Adjudicated by the Clinical Events Committee (CEC)	**TTVR+OMT (N=76)** **30 days**	**6 months**	**OMT (N=42)** **6 months**
All-cause mortality	1 case (1.3%)	1 case (1.3%)	1 case (2.4%)
New-onset renal failure	2 cases (2.6%)	2 cases (2.6%)	0
Myocardial infarction	0	0	0
Stroke	0	0	0
Non-elective TV reintervention	3 cases (3.9%)	4 cases (5.3%)	1 case (2.4%)
Major bleeding	4 cases (5.3%)	4 cases (5.3%)	0
Major cardiac structural complications	1 case (1.3%)	1 case (1.3%)	0
Major access site and vascular complications	0	0	0
Device-related pulmonary embolism	0	0	0
New pacemaker implantation due to AV block	1 case (1.3%)	2 cases (2.6%)	0
Composite events rate	8 case (10.5%)	10 cases (13.2%)	1 case (2.4%)

Despite the complex clinical conditions and severe regurgitation in the enrolled patients, the 6-month follow-up results from the TRAVEL III study demonstrate that the combination of LuX-Valve Plus and medical therapy provides significant clinical benefits over medical therapy alone, while maintaining an excellent procedural success rate and a manageable incidence of adverse events. LuX-Valve Plus offers an encouraging treatment option for patients with severe tricuspid regurgitation, addressing a significant unmet clinical need.

2-YEAR FOLLOW-UP RESULTS OF THE LUX-VALVE PLUS TRAVEL II STUDY

TRAVEL II is a prospective, multi-center, single-arm clinical trial conducted in China, which primarily evaluates the long-term safety and efficacy of LuX-Valve Plus in application on patients with severe tricuspid regurgitation ("**TR**") and enrolled a total of 96 patients from 15 centers across China. This announcement reveals the 2-year long-term follow-up results of this study.

Patients enrolled in the study, on average, aged 71.4 and scored 9.1% as to STS. Among them, 79.2% had atrial fibrillation, 38.5% Severe TR, 27.1% Massive TR, and 34.4% Torrential TR.

The clinical results showed:

(1) The device success rate was 96.8% and the procedural success rate was 95.8%; and

(2) The average device operation time was 35.6±20.8 minutes.

The efficacy results showed:

(1) In terms of improvement in the TR grade, efficacy of 2-year follow-up stayed steady, and none of the patients developed severe or higher-grade TR; valve has been functioning stably in the long run, with a mean transvalvular pressure gradient of 2.37±0.88 mmHg at 30 days, 2.6±1.3 mmHg at one year, and 2.76±1.30 mmHg at two years, remaining at extremely low levels in the long run;

(2) In terms of cardiac function improvement, 96.8% of the patients achieved postoperative cardiac function class I/II at the 2-year follow-up;

(3) In terms of quality of life improvement, the Kansas City Cardiomyopathy Questionnaire scores and 6-minute walking distance for patients improve steadily; in addition, systemic congestion continued to resolve, and rehospitalization due to heart failure within two years remained low.

The safety results showed:

Composite Events (FAS, N=96)	**30 days**	**12 months**	**2 years**
All-cause mortality	1 case (1.0%)	4 cases (4.2%)	5 cases (5.2%)
New-onset renal failure	1 case (1.0%)	1 case (1.0%)	1 case (1.0%)
New-onset liver failure	0	0	0
Severe paravalvular leakage	2 cases (2.1%)	2 cases (2.1%)	2 cases (2.1%)
New onset III°AVB requiring permanent pacemaker implantation	1 case (1.0%)	2 cases (2.1%)	2 cases (2.1%)
Requirement of ECMO or IABP	0	0	0
Myocardial infarction	0	0	0
Strokes	0	2 cases (2.1%)	2 cases (2.1%)
Non-elective TV reintervention	3 cases (3.1%)	3 cases (3.1%)	3 cases (3.1%)
Heart perforation, vascular injury	0	0	0
Life-threatening massive bleeding	0	0	0
Composite events rate	9 cases (9.4%)	16 cases (16.7%)	17 cases (17.7%)

Note: For the 2-year follow-up results, only 1 out of 17 cases of composite MAEs occurred after the 12-month follow-up period; no device-related pulmonary embolism, life-threatening massive bleeding or major cardiac structural events occurred during the 2-year follow-up period.

The results of 2-year clinical follow-up of TRAVEL II study showed that LuX-Valve Plus demonstrated promising long-term clinical performance which remained low in safety events, long-term valve function stability and continued improvement in efficacy over a longer clinical observation period, enabling the patients to have more enhanced cardiac function, better quality of life and sustained clinical benefits.

As of the date of this announcement, over 1,200 implantation cases have been completed worldwide for LuX-Valve Plus transcatheter tricuspid valve replacement system products independently developed by the Company and the longest follow-up record was over 7 years. The product has obtained EU MDR CE certification. It has also received the US FDA's approval on the Pivotal IDE trial, and has obtained the CMS approval of the Category B Medicare Coverage, with both the standard-of-care and the investigational device being covered and being reimbursed. The study comprehensively strengthened the evidence-based medical foundation for the product by examining aspects such as its clinical effectiveness and its long-term durability as demonstrated in randomized controlled trials.

The Company's comprehensive product lines for the tricuspid, mitral, and aortic valves, including their multiple research achievements and clinical application advantages, have successively garnered significant attention and widespread acclaim from experts and scholars worldwide at the TCT 2026 Conference. Leveraging the unique and advanced product designs, diverse product portfolio, outstanding clinical performance in key regions worldwide and extensive experience with successful clinical applications, the Company will continue to advance the global clinical adoption and commercialization of our product portfolio, providing innovative treatment options for more patients with structural heart disease.

Cautionary Statement as required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that the Company will ultimately develop, market and/or commercialize LuX-Valve Plus successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Jenscare Scientific Co., Ltd.
Mr. PAN Fei
Executive Director and Chief Executive Officer

Hong Kong, November 2, 2026

As at the date of this announcement, the executive Director is Mr. PAN Fei; the non-executive Directors are Mr. LV Shiwen, Mr. TAN Ching, Mr. ZHENG Jiaqi, Ms. XIE Youpei and Mr. CHEN Xinxing; and the independent non-executive Directors are Dr. LIN Shoukang, Ms. DU Jiliu and Dr. MEI Lehe.